Altimmune, Inc. - Common Stock (NQ:ALT)

3.610 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Volume	4,273,481
Open	3.600
Bid (Size)	3.600 (6,600)
Ask (Size)	3.610 (4,500)
Prev. Close	3.610
Today's Range	3.520 - 3.625
52wk Range	2.900 - 7.830
Shares Outstanding	95,598,665
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Via Stocktwits

Performance

YTD	-49.2%	-49.2%
1 Month	-26.8%	-26.8%
3 Month	-4.2%	-4.2%
6 Month	-14.7%	-14.7%
1 Year	-50.7%	-50.7%

More News

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

October 06, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via NewMediaWire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via TheNewswire.com

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 05, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

October 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via NewMediaWire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via TheNewswire.com

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via NewMediaWire

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via TheNewswire.com

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

September 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

September 30, 2025

From DJS Law Group

Via Business Wire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

September 30, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025

September 30, 2025

From Berger Montague

Via GlobeNewswire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

September 30, 2025

Via NewMediaWire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

September 30, 2025

Via TheNewswire.com

ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Before the October 6th Deadline in the Altimmune Class Action Lawsuit

September 29, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

Via Benzinga

Investors Who Lost Money on Altimmune, Inc. (ALT) Should Contact Levi & Korsinsky About Pending Class Action - ALT

September 29, 2025

Via NewMediaWire

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?

Yes, Altimmune, Inc. - Common Stock is publicly traded.

What exchange does Altimmune, Inc. - Common Stock trade on?

Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Altimmune, Inc. - Common Stock?

The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market

What is the current price of Altimmune, Inc. - Common Stock?

The current price of Altimmune, Inc. - Common Stock is 3.610

When was Altimmune, Inc. - Common Stock last traded?

The last trade of Altimmune, Inc. - Common Stock was at 12/31/25 04:00 PM ET

What is the market capitalization of Altimmune, Inc. - Common Stock?

The market capitalization of Altimmune, Inc. - Common Stock is 345.11M

How many shares of Altimmune, Inc. - Common Stock are outstanding?

Altimmune, Inc. - Common Stock has 345M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.